BIO-TECHNE Corp vs Clear Secure Inc — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Clear Secure Inc trades at $57.03 (market cap $5.76B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Clear Secure Inc pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| TECH | YOU | |
|---|---|---|
Market Cap | $11.16B | $5.76B |
Sector | Health | Technology |
52-Week High | $72.12 | $62.36 |
52-Week Low | $43.31 | $28.84 |
Enterprise Value | $11.24B | $5.07B |
Dividend Yield | 0.45% | 1.05% |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Clear Secure (YOU) trades at $57.18, up 2.05% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and impressive 81.15% ROE, though valuation multiples remain elevated with a P/E of 44.82. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected, while analyst sentiment remains divided with equal buy/hold ratings.
The stock presents growth potential with expanding revenue and profitability, but faces valuation concerns and competitive pressures. Key catalysts include continued airport expansion and AWS partnership, while risks involve execution challenges and market volatility. The consensus price target of $56.67 suggests limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →